As oncology drug costs continue to rise and many patients experience financial distress in part owing to out-of-pocket drug costs, calls to reduce oncology drug prices are gaining public support and political traction.1,2 However, politically viable policy interventions will not be free and will entail tradeoffs that may reduce patient access to cancer medications.
Ramsey SD, Lyman GH, Bangs R. Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs: Pick Your Poison. JAMA Oncol. 2016;2(4):425–426. doi:10.1001/jamaoncol.2015.5813
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.